Slides
Page 1
COPYRIGHT ABCELLERA AbCellera Corporate Overview August 2026 AbCellera
Page 2
DISCLAIMER 2 COPYRIGHT © ABCELLERA These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC on February 2, 2026 and in the other documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Corporate Overview
Page 3
3 COPYRIGHT © ABCELLERA Corporate Overview We are a clinical-stage biotech company focused on developing novel antibody medicines Founded: 2012 Employees: ~600 Locations: Vancouver & Montreal, Canada Sydney, Australia IPO: December 2020 Platform ~$1B in total platform investmentsWe have built a fully integrated antibody drug platform from discovery to clinical manufacturing and development. As of June 30, 2026 1. AbCellera-led programs 2. Partner-led programs, including under Trianni licenses, understood to be progressing in the clinic. Partnerships 100+ partner-led programs supported 40+ partnersWe formed partnerships with companies that bring novel biology or technology. 12 molecules in the clinic2 We are advancing an internal pipeline of programs. 20+ internal program starts 2 molecules in the clinic1 Programs 2 molecules in IND-enabling activities 300K+sq ft of research and manufacturing facilities As of June 30, 2026 We continue to maintain a strong liquidity position to execute on our strategy $565M+ in total cash balances & marketable securities 3yrs+ of funding for pipeline investments Liquidity $110M in available government funding
Page 4
4 COPYRIGHT © ABCELLERA Corporate Overview Our platform was built through 10+ years of drug discovery partnerships Since 2014, we have partnered with some of the industry’s most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenue in the form of research payments and long-term potential revenue in the form of royalty stakes in those drug programs. In 2023, we shifted our focus from partnerships to advancing a pipeline of internal programs. partner-led programs supported molecules from partner-led programs are understood to be progressing in the clinic* 100+ 12 AbbVie *As of June 30, 2026
Page 5
5 COPYRIGHT © ABCELLERA Corporate Overview Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assets STRATEGY Discovery for GPCR and ion channel targets Novel modalities, including multispecifics and ADCs Indication agnostic
Page 6
6 COPYRIGHT © ABCELLERA Corporate Overview Two programs in the clinic, two programs in IND-enabling activities, and 20+ programs in discovery INTERNAL PIPELINE 20+ discovery programs in the pipeline MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase 1 Phase 2 Phase 3 ABCL635 NK3R Endocrinology & Women’s Health ABCL575 OX40L Immunology & Inflammation ABCL688 Undisclosed GPCR / ion channel Autoimmunity ABCL386 Undisclosed Oncology As of June 30, 2026
Page 7
7 COPYRIGHT © ABCELLERA Corporate Overview All pipeline programs progressing, and ABCL635 Phase 2 top-line data readout supports advancement to late-stage development 2026 PRIORITIES Expect to nominate at least 1 additional development candidate for IND-enabling activities ABCL635 Phase 2 clinical trial top-line readout on Aug 10, 2026 ABCL575 Phase 1 clinical trial top-line readout expected in Q4 2026 ABCL688 progressing through IND-enabling activities ABCL386 progressing through IND-enabling activities Week 4 readout Dosing complete
Page 8
8 COPYRIGHT © ABCELLERA Corporate Overview Q1 Q2 Q3 Q4 Two readouts in 2026 & potential for multiple catalysts in 2027 2026 ABCL635 Menopausal VMS ABCL635 VMS in Oncology ABCL575 Inflammation & Autoimmunity ABCL386 Oncology ABCL688 Autoimmunity New Development Candidate Development candidate selection Phase 1/2 Phase 1 Additionally, 20+ discovery programs in the pipeline anticipated to produce 1-2 development candidates per year IND-enabling IND-enabling 2027 Late-stage development of ABCL635 in menopausal VMS Potential catalysts in 2027 Initiation of Phase 2 studies of ABCL635 in oncology VMS Options for out-licensing of ABCL575 IND submissions and initiation of Phase 1/2 study in patients for ABCL688 and ABCL386 and selection of a new development candidate Readouts Expected readout
Page 9
9 COPYRIGHT © ABCELLERA Corporate Overview Internal Programs
Page 10
10 COPYRIGHT © ABCELLERA Corporate Overview Internal ProgramsABCL635
Page 11
11 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 is an investigational potential best-in-class antibody for the non-hormonal treatment of moderate-to-severe vasomotor symptoms First GPCR-targeting antibody from our platform to advance into our internal pipeline Additional opportunities in oncology Target Neurokinin 3 receptor (NK3R) Indication Moderate-to-severe vasomotor symptoms (VMS) due to menopause Target Type G protein-coupled receptor (GPCR) Status Phase 2 ABCL635
Page 12
12 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 could help to address a large unmet need for the treatment of VMS due to menopause and cancer treatments Symptoms: Sudden and intense feeling of heat that leads to sweating, chills, and interrupted sleep.2 Market Opportunity VMS Due to Menopause 1M+ women could benefit from safe and effective non-hormonal treatments.3 VMS Due to Menopause 4+ years is the median duration for vasomotor symptoms post final menstrual period.1 ~12M women in the US experience moderate-to-severe VMS.3 >6M of which seek treatment.3 ~20% for whom hormone therapy is unsuitable due to contraindications or other factors.4 1. Avis et al., JAMA Intern Med., 2015. 2. Nappi et al., Menopause, 2021. 3. Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. 4. Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. 5. Management estimate based on Wholesale Acquisition Cost of Veozah and Lynkuet (accessed from Micromedex Red Book) and above sources. Actual market size may differ. $6B+ Total Addressable Market estimated for non-hormonal treatments assuming only current small-molecule gross prices as >$5K per patient per year.5 ABCL635 Opportunity ● Breast cancer ● Prostate cancer ● Ovarian cancer VMS Due to Cancer Treatment Many patients experience VMS during cancer treatment that includes hormone deprivation for:
Page 13
13 COPYRIGHT © ABCELLERA Over 1 million women in the US are estimated to need a non-hormonal treatment for moderate-to-severe VMS due to menopause Corporate Overview ABCL635 Market Opportunity Contraindicated for MHT ~12M women in the US with moderate-to-severe VMS due to menopause1 6M+ >50% seek treatment1 <50% do not seek treatment1 80% successfully treated with or remaining eligible for MHT2 MHT not tolerated Eligible for MHT 1M+ ~20% in need of non-hormonal treatment2 1. Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. 2. Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. Actual market size may differ.
Page 14
14 COPYRIGHT © ABCELLERA Corporate Overview NK3R antagonists are effective, non-hormonal options for VMS ABCL635 Science Reproductive State
Page 15
15 COPYRIGHT © ABCELLERA Corporate Overview NK3R antagonists are effective, non-hormonal options for VMS ABCL635 Menopause Science
Page 16
16 COPYRIGHT © ABCELLERA Corporate Overview NK3R antagonists are effective, non-hormonal options for VMS ABCL635 Treatment Science Proposed mechanism of action for ABCL635 based on AbCellera clinical data and published literature.
Page 17
17 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Differentiation Recently approved NK3R therapies are building the market Small molecule NK3R antagonist Approved by US FDA on May 12, 2023 Stage Daily oral treatment Dosing ● Effective in reducing severity and frequency of VMS. ● Boxed warning for liver toxicity. Requires liver monitoring. Fezolinetant Small molecule NK3R and NK1R antagonist Approved by US FDA October 24, 2025 Stage Daily oral treatment Dosing ● Effective in reducing severity and frequency of VMS. ● Warnings for CNS depressant effect, daytime impairment, and liver enzyme elevation. Requires liver monitoring. Elinzanetant CNS: Central nervous system
Page 18
18 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Phase 1 data supported advancing to Phase 2 Favorable tolerability profile with no observed liver toxicity PK profile supports once monthly subcutaneous dosing Biomarker data suggests strong and sustained engagement of NK3R Demonstrated suppression of testosterone, LH, and FSHAll doses tested generally well tolerated Estimated half-life of ~24 days ABCL635 PHASE 2 DOSE SELECTION A 600 mg SC dose administered once best approximates 300 mg SC at steady state* and is being evaluated in the Phase 2 study SC: subcutaneous. * Based on a comparison of predicted Cmax at steady state of a 300 mg dose once every 4 weeks, vs. the Cmax from a single dose of 600 mg. SAFETY/TOLERABILITY ENDPOINT PHARMACOKINETIC ENDPOINT PHARMACODYNAMIC ENDPOINT ABCL635 Development
Page 19
19 COPYRIGHT © ABCELLERA Corporate Overview Phase 2 data at week 4 suggest ABCL635 has the potential to be a best-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) Dosing convenience with long-acting subcutaneous self-injection Data supports an improved safety profile with reduced liver and gastrointestinal findings Markedly improved efficacy data compared to available non-hormonal therapies DISCLAIMER: Information provided above is for illustrative purposes only and no head-to-head clinical trials have been conducted. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across trials. ABCL635 Differentiation
Page 20
20 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Phase 2 Top-line Data at Week 4
Page 21
21 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Phase 2 is a randomized, double-blind, placebo-controlled, multicenter trial in postmenopausal women Phase 2 Study Trial Design Participants N ~ 80 planned 92 postmenopausal women with moderate-to-severe VMS N=46 per cohort Key inclusion criteria Comparable to Phase 3 entry criteria for approved NK3R small molecules Age 40-75 years Endpoints VMS frequency, VMS severity, patient-reported outcome measures, safety, pharmacokinetics Efficacy analysis population/ Primary analysis methodology Intent to treat population at 4 weeks MMRM analyses except for patient global impression of change (Mann-Whitney U test) Study design Placebo-controlled treatment period ABCL635 600 mg SC (N=46) Placebo (N=46) Open-Label Extension 600 mg SC Optional open-label extension (OLE) Screening R NK3R: Neurokinin 3 Receptor; MMRM: Mixed Models for Repeated Measures; SC: subcutaneous. Clinicaltrials.gov ID: NCT07118891.
Page 22
22 COPYRIGHT © ABCELLERA Corporate Overview The moderate/severe VMS severity score is calculated as: (number of moderate hot flashes x 2) + (number of severe hot flashes x 3) / VMSM-S Frequency. The PGI-S is on a five-point scale ranging from "none" to "very severe". BMI: Body Mass Index; PGI-S: Patient Global Impression of Severity; SC: subcutaneous. NK3R: Neurokinin 3 Receptor; Data cutoff: 30JUL26 Demographic and baseline characteristics were well balanced ● Baseline characteristics, including severity of disease, consistent across treatment groups ● Baseline data comparable to studies of small molecule NK3R inhibitors Phase 2 Population ABCL635 (600 mg) Once Monthly, SC (N=46) Placebo Once Monthly, SC (N=46) Race, n (%) Asian 1 (2.2) 1 (2.2) Black 2 (4.3) 3 (6.5) White 43 (93.5) 42 (91.3) Age (years) Mean (Min, Max) 58.7 (47, 69) 59.7 (49, 71) BMI (kg/m2) Mean (Min, Max) 27.1 (20.8, 33.9) 27.4 (21.1, 34.9) Patient Global Impression of Severity (PGI-S), n (%) Mild 0 1 (2.2) Moderate 18 (39.1) 19 (41.3) Severe 22 (47.8) 18 (39.1) Very Severe 6 (13.0) 8 (17.4) Frequency of moderate/severe VMS, daily average Mean (Median) 10.6 (8.8) 9.8 (9.1) Moderate/severe VMS Severity Score, daily average Mean (Median) 2.4 (2.4) 2.4 (2.5) PROMIS-SD-SF-8b Total T -Score Mean (Median) 58.8 (57.8) 57.2 (56.3)
Page 23
23 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 reduced the frequency of moderate and severe VMS starting at week 1 through week 4 MMRM: Mixed Models for Repeated Measures; LSM (SE): Least Squares Mean (Standard Error); VMSM-S: moderate and severe VMS Data cutoff: 30JUL26 Frequency of Moderate and Severe VMS ● Mean placebo-adjusted treatment difference of 2.6 at week 1 ● Mean placebo-adjusted treatment difference of 5.3 starting at week 4 ● Mean % change from baseline at week 4: ○ 83% reduction ABCL635 vs. 33% reduction placebo ○ placebo-adjusted difference of 50% ● Treatment effects consistent across subgroup and sensitivity analyses Primary MMRM analysis Sensitivity MMRM analysis
Page 24
24 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 reduced the severity score of moderate and severe VMS starting at week 1 through week 4 MMRM: Mixed Models for Repeated Measures; LSM (SE): Least Squares Mean (Standard Error); VMSM-S: moderate and severe VMS. Data cutoff: 30JUL26 Severity Score of Moderate and Severe VMS ● Mean placebo-adjusted treatment difference of 0.3 at week 1 ● Mean placebo-adjusted treatment difference of 1.1 at week 4 ● Mean % change from baseline at week 4: ○ 58% reduction ABCL635 vs. 12% reduction placebo ○ placebo-adjusted difference of 46% ● Treatment effects consistent across subgroup and sensitivity analyses Primary MMRM analysis Sensitivity MMRM analysis
Page 25
25 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 reduced the severity score of moderate and severe VMS starting at week 1 through week 4 ● Mean ABCL635 severity at week 4 = 1.0 (mild) ● Mean placebo severity at week 4 = 2.1 (moderate) SE: Standard Error; VMSM-S: moderate and severe VMS. Data cutoff: 30JUL26
Page 26
26 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 participants fared better than placebo across all threshold values VMSM-S: moderate and severe VMS. Data cutoff: 30JUL26 Cumulative Distribution at Week 4 of VMS Moderate-to-Severe Frequency and Severity Scores VMS Frequency VMS Severity % Reduction from baseline at week 4 ABCL635 (N=46) % Participants Placebo (N=46) % Participants 100% 37.0% 2.2% >90% 60.9% 8.7% >75% 78.3% 15.2% >50% 87.0% 32.6% % Reduction from baseline at week 4 ABCL635 (N=46) % Participants Placebo (N=46) % Participants 100% 26.1% 2.2% >90% 28.3% 2.2% >75% 37.0% 2.2% >50% 58.7% 8.7%
Page 27
27 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 significantly improved sleep starting at week 1 through week 4 PROMIS-SD-SF-8b: Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b; LSM (SE): Least Squares Mean (Standard Error). Data cutoff: 30JUL26 PROMIS-SD-SF-8b Total T -Score Change from Baseline ● Significant treatment difference of -5.5 at week 4 ● Improvements observed across all 8 aspects of sleep disturbance including: ○ Trouble sleeping ○ Difficulty falling asleep ○ Difficulty staying asleep ○ Getting enough sleep ○ Restlessness ○ Sleep quality ○ Satisfaction with sleep ○ Feeling refreshed
Page 28
28 COPYRIGHT © ABCELLERA Corporate Overview 84% of ABCL635 patients rated symptoms as “Much Better” or “Moderately Better” vs. 27% of placebo patients Data cutoff: 30JUL26 Patient Global Impression of Change (PGI-C) at Week 4 ● Significant differences observed as early as week 1 ● Benefits persisted throughout 4 weeks
Page 29
29 COPYRIGHT © ABCELLERA Corporate Overview ● No SAEs or severe (Grade 3+) AEs in ABCL635 group ● 1 SAE and 2 severe (Grade 3) AEs in placebo group ● Headache AEs generally mild in both treatment groups ● Fatigue AEs all mild in ABCL635 group and mild/moderate in placebo group ● No evidence of gastrointestinal toxicity ● 1 ABCL635 AE of mild increase in transaminases (AST = 92; AL T = 66 IU/L), resolved in one week ● 1 placebo patient with AL T values up to 121 IU/L *Includes Headache and Tension headache ^ Includes injection site bruising, injection site reaction, injection site erythema, injection site hyperesthesia, injection site induration, and injection site pruritus. SAE: Serious Adverse Event; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; Data cutoff: 30JUL26 ABCL635 demonstrates a favorable tolerability profile Adverse Events (AEs) reported in at least two patients in either group regardless of relationship during first 4-weeks of treatment AE Preferred Term ABCL635 (600 mg) Once Monthly, SC (N=46) n (%) Placebo Once Monthly, SC (N=46) n (%) Number (%) with at least one AE 31 (67.4%) 24 (52.2%) Number (%) with at least one SAE 0 1 (2.2%) Number (%) with at least one grade 3+ AE 0 2 (4.3%) Headache* 13 (28.2%) 6 (13.0%) Fatigue 6 (13.0%) 3 (6.5%) Injection site reaction^ 4 (8.7%) 3 (6.5%) Nausea 2 (4.3%) 4 (8.7%) Nasopharyngitis 2 (4.3%) 3 (6.5%) Gastroesophageal reflux disease 2 (4.3%) 0 Urinary tract infection 2 (4.3%) 0 Diarrhea 0 3 (6.5%) Nasal congestion 1 (2.2%) 2 (4.3%) Abdominal pain 0 2 (4.3%) Arthralgia 0 2 (4.3%) Dizziness 0 2 (4.3%)
Page 30
30 COPYRIGHT © ABCELLERA Corporate Overview No liver safety signal observed to date Mean liver function tests (ALT, AST, bilirubin) remained stable Data are shown as mean ± SEM. The mean upper limit of normal (ULN) reported across all measurements is shown in the dotted lines. Data cutoff: 30JUL26 Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Bilirubin
Page 31
31 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Phase 2 efficacy data are markedly improved compared to approved small molecule NK3R antagonists at week 4 *Veozah (fezolinetant) USPI, **Lynkuet (elinzanetant) USPI DISCLAIMER: Information provided above is for illustrative purposes only and no head-to-head clinical trials have been conducted. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across trials. VMS Moderate-to-Severe Frequency and Severity Placebo-Adjusted at Week 4 Frequency Severity ABCL635 SC 600 mg Fezolinetant 45 mg -Trial 1* Fezolinetant 45 mg -Trial 2* Elinzanetant 120 mg -Trial 1** Elinzanetant 120 mg -Trial 2** ABCL635 SC 600 mg Fezolinetant 45 mg -Trial 1* Fezolinetant 45 mg -Trial 2* Elinzanetant 120 mg -Trial 1** Elinzanetant 120 mg -Trial 2**
Page 32
32 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Phase 2 data indicate best-in-class potential and supports advancing to late-stage development Potential for best-in-class VMS efficacy EFFICACY ENDPOINT ● Additional data to be presented at major medical conferences later this year ● Completion of 12-week follow up to support optimal dose selection ● Regulatory interactions to discuss late-stage development in VMS due to menopause and oncology treatments NEXT STEPS Significant improvement in sleep and symptom burden Comprehensive improvement in sleep disturbance symptoms QUALITY OF LIFE ENDPOINT Significant reduction in both VMS frequency and severity vs. placebo after a single dose EFFICACY ENDPOINT Favorable tolerability profile with no meaningful liver or gastrointestinal safety signal Potential for an improved safety profile SAFETY ENDPOINT
Page 33
33 COPYRIGHT © ABCELLERA Corporate Overview Internal ProgramsABCL575
Page 34
34 COPYRIGHT © ABCELLERA Corporate Overview ABCL575 is an investigational antibody for the treatment of atopic dermatitis OX40 Ligand (OX40L) Target Atopic Dermatitis (AD) Indication Immunology & Inflammation Therapeutic Area Phase 1 Status AbCellera intends to complete Phase 1 studies and currently has no plans to develop ABCL575 past Phase 1, remains open to partnering. ABCL575
Page 35
35 COPYRIGHT © ABCELLERA Corporate Overview Royalty Portfolio & Partnered Programs
Page 36
36 COPYRIGHT © ABCELLERA Corporate Overview AbCellera has a portfolio of downstream stakes. 1 Understood to be progressing. Number of PARTNER-LED PROGRAMS WITH DOWNSTREAMS1 35 Number of MOLECULES IN THE CLINIC WITH DOWNSTREAMS1 12 Trianni license AbCellera-led Partner-led As of June 30, 2026 Preclinical and discovery In the clinic
Page 37
37 COPYRIGHT © ABCELLERA Corporate Overview 12 molecules with downstream participation are currently understood to be progressing. MOLECULE MOST ADVANCED STAGE THERAPEUTIC AREA(S) PARTNER PROGRAM TYPE ABCL635 Phase 2 • endocrinology / women's health n/a AbCellera-led ABCL575 Phase 1 • immunology and inflammation undisclosed Phase 1 • neuroscience Teva Pharmaceuticals Partner-ledundisclosed Pivotal studies • animal health Dechra IVX-01 Clinical field study • animal health AB-2100 Phase 1/2 • oncology ArsenalBio Trianni license AB-3028 Phase 1/2 • oncology GIGA-564 Phase 1 • oncology GigaGen NBL-012 Phase 2-ready1 • dermatology • gastrointestinal disease • immunology NovaRockNBL-015/FL-301 Phase 11 • oncology NBL-020 Phase 11 • oncology NBL-028 Phase 11 • oncology As of June 30, 2026 1 As represented by partner.
Page 38
38 COPYRIGHT © ABCELLERA THANK YOU